Log In
Print
BCIQ
Print
Print this Print this
 

BOW015 (formerly BOW-015)

  Manage Alerts
Collapse Summary General Information
Company Epirus Biopharmaceuticals Inc.
DescriptionBiosimilar of infliximab, a chimeric mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner

Ranbaxy Laboratories Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today